Adding Toripalimab to Chemotherapy Improves Survival in Advanced NSCLC
Adding toripalimab to first-line chemotherapy improves overall survival in patients with advanced non-small cell lung cancer, a phase 3 study suggests.
All articles by James Nam, PharmD
Adjuvant Chemotherapy Superior to Toripalimab in Resected Mucosal Melanoma
Chemotherapy is more effective than toripalimab as adjuvant therapy in patients with resected mucosal melanoma, a study suggests.
Nimorazole Provides No Benefit in Head and Neck Cancers With Tumor Hypoxia
Adding nimorazole to radiotherapy does not improve outcomes in patients with locally advanced head and neck cancer who have tumor hypoxia, phase 3 data suggest.
Adding Talazoparib to Atezolizumab Maintenance Improves PFS in SLFN11+ ES-SCLC
Adding talazoparib to atezolizumab maintenance can improve progression-free survival in patients with SLFN11+ extensive-stage small cell lung cancer, a phase 2 trial suggests.
Elotuzumab Improves Upon KRd in Newly Diagnosed Multiple Myeloma
Adding elotuzumab to carfilzomib, lenalidomide, and dexamethasone leads to deeper remissions in transplant-eligible, newly diagnosed multiple myeloma, data suggest.
Zanidatamab Yields Durable Responses in HER2+ Biliary Tract Cancer
Zanidatamab can produce rapid and durable responses in patients with advanced HER2-positive biliary tract cancer, phase 2 data suggest.
Serious Mental Illness Linked to Longer Hospital Stays After Lung Cancer Resection
Serious mental illness is associated with longer hospital stays among patients undergoing lung cancer resection, according to a new study.
PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
The association between disease progression and PD-1/PD-L1 inhibitors in non-small cell lung cancer is unknown.
S-1 Plus Carboplatin May Be Effective in NSCLC Patients With Interstitial Lung Disease
Patients with severe complications, such as interstitial lung disease, are often excluded from clinical studies assessing chemotherapy in NSCLC.
Elotuzumab May Improve Outcomes Without Negatively Impacting HRQoL in Multiple Myeloma
Previous studies showed that elotuzumab plus lenalidomide and dexamethasone improved progression-free survival and response rates, but its impact on patient-reported outcomes is unknown.
- Loading...
Loading...
Next post in Multiple Myeloma
Loading... 
Loading...